The size of the plasma protein therapeutics market in the Asia Pacific is currently estimated at USD 5477.43 Million in 2022. It is further forecasted to reach USD 9494.70 Million by 2027, growing at a significant CAGR of 11.63% during the forecast period.
The number of blood donations is rapidly growing year-over-year in the APAC region, which is estimated to favor this region's plasma protein therapeutics market. Many awareness camps are helping people to understand the importance of blood donations. In addition, there are many new technological advancements in the plasma protein therapeutics market, such as introducing the new and less costly method to separate protein from plasma, increasing the demand for the APAC plasma protein therapeutics market significantly.
New types of plasma therapies deal with infectious diseases such as Rabies, Tetanus, Hepatitis A&B, and varicella much effectively. With the increase in the number of diseases like these, the market is expected to grow rapidly. Therefore, these new plasma protein therapies are increasing the demand for the APAC plasma protein therapeutics market.
The plasma proteins are started to produce new opportunities in the pharmaceutical market, and they are helping the treatment of various diseases such as hemostasis. Many new treatment methods are being introduced with the help of plasma proteins, increasing the efficiency of the result and helping the growth of the APAC plasma protein therapeutics market. With the help of plasma protein, people can find out about diseases like genetic disorder diseases in the starting stages, which helps treat the disease. This increases the demand for the plasma protein therapeutics market. Furthermore, as the use of targeted therapies is growing worldwide, a new type of therapy is being introduced to increase the effectiveness of the treatment according to the conditions of each patient. This is increasing the growth of the Plasma Protein Therapeutics Market. Plasma proteins are vital for the desired outcome of the treatment with these new therapy treatments.
However, strict government rules are one of the significant drawbacks of the APAC plasma protein therapeutics market. In addition, the complex process of manufacturing and using is hampering the growth of the market.
This research report on the Asia Pacific plasma protein therapeutics market has been segmented and sub-segmented into the following categories:
By Type:
By Application:
By Country:
During the forecast period, the APAC market is expected to project the fastest growth rate among all the regions in the global market. This is because the applications of plasma proteins are increasing in the pharmaceutical sector. In addition, a new method of separating protein from the plasma can be done with low cost and outstanding efficiency. These recent technological advancements are expected to drive the market in the coming years.
With new therapy methods, the growth of the Plasma Protein Therapeutics Market is increasing in the Asia Pacific. These are mainly dominating in China and India because of government support and high awareness among the people. These are the main factors that will help the growth of the market rapidly in the coming years.
In the plasma protein market of Asia Pacific, with an increasing population and rising demand for advanced therapeutics, China is expected to have the highest share. With this rising demand, Chinese industry key players are interested in the APAC Plasma Protein Therapeutics Market.
KEY MARKET PLAYERS:
Companies dominating the APAC Plasma Protein Therapeutics Market profiled in this report are Grifols, CSL Behring, Baxter, Krdrion, China Biologics, Octapharma, Chendu Inst, and Shire Plc.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Type
5.1.1 Immunoglobulins
5.1.2 Albumin
5.1.3 Coagulation Factors
5.1.4 Alpha-1 proteinase inhibitor
5.1.5 Others
5.2 By Application
5.2.1 Hemophilia
5.2.2 Primary Immunodeficiency Disorder
5.2.3 Idiopathic Thrombocytopenic Purpura
5.2.4 Secondary Immunodeficiency
5.2.5 others
6. Geographical Analysis
6.1 Introduction
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 CSL Behring
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Baxter
8.3 Biotest
8.4 China Biologics
8.5 Grifols
8.6 Kedrion
8.7 Octapharma
8.8 Shire Plc.
8.9 Chengdu Inst.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Talk to our analyst and get customised report done according to your research needs
Check if you can avail any discount. Submit your details and our team will get back to you.
Request to avail a free sample report that reflects this market and its growth.
